In 1581 Rembert Dodoens wrote "Medicinalium observationum exempla rara, recognita et aucta" a Latin book about the diagnosis and treatment of disorders with a low prevalence.
The "orphan drug-movement" is believed to have been initiated only recently with the Orphan Drug Act of 1983 in the United States of America, which was intended to stimulate research and commercialization of medicinal products ("orphan drugs") intended for the in-vivo diagnosis, prevention and treatment of diseases with a low prevalence ("rare diseases"). But was there any interest in disorders with a low prevalence before last century?
Rembert Dodoens was a Flemish physician also known as Rembertus Dodonaeus, who was born in Mechelen (now Belgium) on the 29th of June 1517. He did his studies at the Collegium Trilingue ( For surgical procedures Dodoens called upon his local barber-surgeons (amputatio) or stone-cutters (lithotomia). For pharmacological treatment Dodoens referred to his own Cruydenboeck (Book of Herbs, Mechelen, 1554) with "Plaetse, Tijt, Naem, Natuere, Kracht ende Werckinghe" (growing place and time, name, identification, pharmacological activity) of 942 plants. Operating procedures for the production of his "orphan drugs" from plant material (bolus, confectio, decoctum, electuarium, hostia, pilula, potio, pulvis, syrupus, trochiscus for internal use and balneum, cauterium, clysterium, collyrium, emplastrum, gargarisma, lotio, unguentum for external use) are given at the end of some monographs.
The standardization of these compounding procedures by local pharmacists continued further with the publication of several city and (supra)national pharmacopoeias. Only at the end of the 19th century the pharmaceutical industry will take over the manufacturing of medications. In 2012, the European Medical Agency accorded a Market Authorization to the orphan drug Nexobrid, a purified extract from pineapple (Ananas comosus). Colchicine, the active ingredient of Colchicum autumnale (Cruydenboeck Part 3, Plant 40), is still used today offlabel for the treatment of ultra-rare auto-inflammatory diseases. Off-label use was not mentioned as the FDA required the first package insert only in 1968. Home therapy was done by pharmacists administering clysters at home.
Throughout the Middle Ages, to be diagnosed with a (rare) disease had major social ("stigmatization") and medicinal implications for the individual. Some communities, knowing the importance of an accurate diagnosis, established multidisciplinary groups ("expert centers") to review suspected cases. Representatives of the church, physicians and people with the disease ("patients' representatives") were typically members of these groups. Cousin marriage was common at that time in Europe, which most probably resulted in multiple genetic diseases. These disorders could not yet be diagnosed on DNA as James Watson and Francis Crick discovered the double helix only in 1953. The first description of a rare disease attributed to inheritance (alkaptonuria) was by Archibald Garrod in 1902 on the basis of proteins not DNA. Children were born at home from teenage housewives sometimes with the help of a midwife following the guidelines of Eucharius Rhodion's Der Rosengarten (1513). Long-time breastfeeding by the mother or by a wet nurse was general practice. Infanticide became exceptional in the 16th century, and unwanted children were left at the door of church or abbey, and the clergy was assumed to take care of their upbringing.
William Harvey (1578-1657) was the first to describe correctly the systemic circulation of blood pumped to the brain and body by the heart. He is also famous for his quote on rare diseases: Nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten path; nor is there any better way to advance the proper practice of medicine than to give our minds to the discovery of the usual law of nature by the careful investigation of cases of rarer forms of disease. For it has been found in almost all things, that what they contain of useful or of applicable nature, is hardly perceived unless we are deprived of them, or they become deranged in some way.
Over the last 500 years at least, there has always been interest on the part of the medical and pharmaceutical profession in the diagnosis and treatment of disorders with a low prevalence. But of course, diagnostic (uroscopy as the lab test) and surgical procedures have changed tremendously over time. Life-style changes (scorbutus/vitamin C; dysenteria/better quality of drinking water) and vaccinations (tetanos/Clostridium) have almost eliminated some and a better understanding of the diseases has led to prevention and better (intravenous) therapy. Compounding medications following Standard Operating Procedures and Good Manufacturing Practice is still practiced today but most of the medicinal products for the prevention, diagnosis and treatment of a limited number of rare diseases are now commercially available. More basic research and randomized clinical trials are needed for the cure of patients with other rare -and ultra-rare-diseases.
